<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="case-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Epilepsy Behav Case Rep</journal-id>
<journal-id journal-id-type="iso-abbrev">Epilepsy Behav Case Rep</journal-id>
<journal-title-group>
<journal-title>Epilepsy &amp; Behavior Case Reports</journal-title>
</journal-title-group>
<issn pub-type="epub">2213-3232</issn>
<publisher>
<publisher-name>Elsevier</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28070485</article-id>
<article-id pub-id-type="pmc">5219608</article-id>
<article-id pub-id-type="publisher-id">S2213-3232(16)30074-3</article-id>
<article-id pub-id-type="doi">10.1016/j.ebcr.2016.11.001</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Vagus nerve stimulation for generalized epilepsy with febrile seizures plus (GEFS<sup>+</sup>) accompanying seizures with impaired consciousness</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hanaya</surname>
<given-names>Ryosuke</given-names>
</name>
<email>hanaya@m2.kufm.kagoshima-u.ac.jp</email>
<xref ref-type="aff" rid="af0005">a</xref>
<xref ref-type="corresp" rid="cr0005">⁎</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Niantiarno</surname>
<given-names>Fajar H</given-names>
</name>
<xref ref-type="aff" rid="af0010">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kashida</surname>
<given-names>Yumi</given-names>
</name>
<xref ref-type="aff" rid="af0005">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hosoyama</surname>
<given-names>Hiroshi</given-names>
</name>
<xref ref-type="aff" rid="af0005">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Maruyama</surname>
<given-names>Shinsuke</given-names>
</name>
<xref ref-type="aff" rid="af0015">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sugata</surname>
<given-names>Sei</given-names>
</name>
<xref ref-type="aff" rid="af0005">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Otsubo</surname>
<given-names>Toshiaki</given-names>
</name>
<xref ref-type="aff" rid="af0020">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tanaka</surname>
<given-names>Kazumi</given-names>
</name>
<xref ref-type="aff" rid="af0025">e</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ishii</surname>
<given-names>Atsushi</given-names>
</name>
<xref ref-type="aff" rid="af0030">f</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hirose</surname>
<given-names>Shinichi</given-names>
</name>
<xref ref-type="aff" rid="af0030">f</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arita</surname>
<given-names>Kazunori</given-names>
</name>
<xref ref-type="aff" rid="af0005">a</xref>
</contrib>
</contrib-group>
<aff id="af0005"><label>a</label>Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan</aff>
<aff id="af0010"><label>b</label>Department of Neurosurgery, Medical Faculty of Diponegoro University, Semarang, Indonesia</aff>
<aff id="af0015"><label>c</label>Department of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan</aff>
<aff id="af0020"><label>d</label>Fujimoto General Hospital, Miyakonojo, Japan</aff>
<aff id="af0025"><label>e</label>Department of Pediatrics, Saiseikai Sendai Hospital, Satsuma-Sendai, Japan</aff>
<aff id="af0030"><label>f</label>Department of Pediatrics, Fukuoka University School of Medicine, Fukuoka, Japan</aff>
<author-notes>
<corresp id="cr0005"><label>⁎</label>Corresponding author at: Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, 890-8544 Kagoshima, Japan.Department of NeurosurgeryGraduate School of Medical and Dental SciencesKagoshima University8-35-1 SakuragaokaKagoshima890-8544Japan <email>hanaya@m2.kufm.kagoshima-u.ac.jp</email></corresp>
</author-notes>
<pub-date pub-type="pmc-release">
<day>09</day>
<month>11</month>
<year>2016</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>09</day>
<month>11</month>
<year>2016</year>
</pub-date>
<volume>7</volume>
<fpage>16</fpage>
<lpage>19</lpage>
<history>
<date date-type="received">
<day>21</day>
<month>9</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>22</day>
<month>10</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>6</day>
<month>11</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© 2016 The Authors</copyright-statement>
<copyright-year>2016</copyright-year>
<license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
</license>
</permissions>
<trans-abstract xml:lang="fr">
<p>Generalized epilepsy with febrile seizures plus (GEFS<sup>+</sup>) is characterized by childhood-onset epilepsy syndrome. It involves febrile seizures and a variety of afebrile epileptic seizure types within the same pedigree with autosomal-dominant inheritance. Approximately 10% of individuals with GEFS<sup>+</sup> harbor SCN1A, a gene mutation in one of the voltage-gated sodium channel subunits. Considerably less common are focal epilepsies including focal seizures with impaired consciousness. We report vagus nerve stimulation (VNS) in a 6-year-old girl with GEFS<sup>+</sup> who exhibited drug-resistant generalized tonic-clonic seizures and focal seizures with impaired consciousness.</p>
</trans-abstract>
<kwd-group id="ks0005">
<title>Keywords</title>
<kwd>Generalized epilepsy with febrile seizures plus (GEFS<sup>+</sup>)</kwd>
<kwd>Generalized tonic-clonic seizures</kwd>
<kwd>Focal seizures with impaired consciousness</kwd>
<kwd>Vagus nerve stimulation (VNS)</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s0005">
<label>1</label>
<title>Introduction</title>
<p>Generalized epilepsy with febrile seizures plus (GEFS<sup>+</sup>) is characterized by childhood-onset epilepsy syndrome with febrile seizures and a variety of afebrile epileptic seizures. Its inheritance is autosomal dominant <xref ref-type="bibr" rid="bb0005">[1]</xref> and its spectrum is comprised of a range of mild to severe phenotypes varying from classical febrile seizures to Dravet syndrome. GEFS<sup>+</sup> patients manifest a mutation encoding voltage-gated sodium channel subunits (SCN1A, SCN1B, SCN2A) and GABA receptor subunits (GABRG2, GABD) <xref ref-type="bibr" rid="bb0005">[1]</xref>. Typically, the mutations are missense mutations, and about 80% of affected individuals present with some form of seizure disorder. Approximately 1/3 of GEFS<sup>+</sup> patients may experience a variety of generalized epilepsies. Some families include individuals with focal epilepsy, particularly temporal lobe epilepsy (TLE) of varying severity <xref ref-type="bibr" rid="bb0010">[2]</xref>. While surgical resection is one treatment option for the drug-resistant focal symptoms of GEFS<sup>+</sup>, due to the genetic defect, children are unlikely to benefit from cortical resection <xref ref-type="bibr" rid="bb0015">[3]</xref>. We treated a girl with an SCN1A mutation and generalized tonic-clonic seizure (GTCS) and focal seizures with impaired consciousness (FSIC) by vagus nerve stimulation (VNS).</p>
</sec>
<sec id="s0010">
<label>2</label>
<title>Case report</title>
<p>This girl had the first febrile seizure at the age of 6 months; in the next 8 months she suffered 6 more febrile seizures. Her first afebrile seizure occurred when she was 2 years old. Multiple antiseizure drugs, i.e. clobazam, valproate, phenobarbital, carbamazepine, lamotrigine, and levetiracetam failed to inhibit her seizures and she was admitted to our hospital when she was 5 years old.</p>
<p>She suffered numerous GTCSs and FSICs each month. Her developmental age was somewhat delayed. Interictal electroencephalography (EEG) showed frequent bilateral synchronous or independent slow spike waves. Long-term video-EEG detected 4 FSICs in the off-drug state. During 3 FSICs we observed conjugate deviation to the left, extension of the left limbs, flexion of the right limbs, and body-axis rotation to left after motion arrest. EEG showed diffuse polyspikes in the right hemisphere followed by high-voltage 12 Hz waves at T6 and O2 (<xref ref-type="fig" rid="f0005">Fig. 1</xref>). During an FSIC observed in the later part of the monitoring period, spike waves began at O1 and T5 with oral automatism, conjugate deviation to the right, and right body-axis rotation. Magnetoencephalography showed a broad dipole cluster in the right posterior temporal-, parietal-, and occipital lobe (<xref ref-type="fig" rid="f0010">Fig. 2</xref>). No abnormalities were detected on MRI-, iomazenil- and IMP-SPECT-, and FDG-PET studies. Preoperative evaluation without intracranial recording failed to localize the epileptogenic area although her symptoms indicated that hers would be a focal seizure. While there were no GTCSs in the afebrile state during the monitoring period, their description by her parents suggested that her GTCSs in the afebrile state were primary GTCSs rather than seizures of secondary generalization. We chose VNS instead of resective surgery.<fig id="f0005"><label>Fig. 1</label><caption><p>Ictal scalp electroencephalograph recorded during a complex partial seizure.</p><p>Note diffuse polyspikes and waves followed by high-voltage 12 Hz waves starting at T6 and O2 (arrow). The 12 Hz waves lasted about 3 min and were dominant in the right hemisphere. The highest amplitude was recorded at T6 and O2.</p></caption><alt-text id="al0005">Fig. 1</alt-text><graphic xlink:href="gr1"></graphic></fig><fig id="f0010"><label>Fig. 2</label><caption><p>Magnetencephalographic findings.</p><p>A cluster of equivalent dipole was observed in the posterior temporal-, parietal-, and occipital lobe. R, right; A, anterior.</p></caption><alt-text id="al0010">Fig. 2</alt-text><graphic xlink:href="gr2"></graphic></fig></p>
<p>A VNS system was implanted when she was 6 years old. Her father and brother had a history of febrile seizures and her sister suffered afebrile seizures. Gene analysis after VNS implantation detected the mutation; SCN1A encoded the α-subunit of a sodium-gated channel. This examination confirmed that her younger sister had the same mutation.</p>
<p>Stimulation started with the standard setting <xref ref-type="bibr" rid="bb0020">[4]</xref> obtained a seizure reduction of an average of 60% and 72% for GTCSs and FSICs, respectively, in the course of 13–24 months after VNS. In the third year after VNS, the average seizure reduction was 80% and 100% for GTCSs and FSICs, respectively (<xref ref-type="fig" rid="f0015">Fig. 3</xref>). While sodium channel blockers exacerbated SCN1A-related seizure disorders, the number of both types of seizure was decreased after the start of VNS. We then replaced carbamazepine with lamotrigine because it had an effect on both GTCSs and FSICs. Her seizures increased again but were reduced by increasing the level of VNS at the fourth year. The stimulation parameters 4 years after the start of VNS were: output current 1.50 mA, frequency 30 Hz, pulse width 500 ms, on-time 7 s, and off-time 0.5 min (duty cycle 30%). In the last 12-month period (43–54 months after the start of VNS), her GTCSs and FSICs were reduced by an average of 90% and 88%, respectively. Her intelligence quotient was in the normal range and she attends a regular elementary school.<fig id="f0015"><label>Fig. 3</label><caption><p>Frequency of seizures, shown at 3-month intervals, and the treatment status before and after the implantation of vagus nerve stimulation (VNS).</p><p>The number of generalized tonic-clonic- and focal seizures with impaired consciousness (GTCSs, FSICs) decreased after VNS.</p><p>CBZ, carbamazepine; LEV, levetiracetam; LTG, lamotrigine; IQ, intelligence quotient measured on the Tanaka-Binet Intelligence Scale.</p></caption><alt-text id="al0015">Fig. 3</alt-text><graphic xlink:href="gr3"></graphic></fig></p>
</sec>
<sec id="s0015">
<label>3</label>
<title>Discussion</title>
<p>GEFS<sup>+</sup> families are grouped into 4 broad subphenotypes, i.e. classical GEFS<sup>+</sup>, borderline GEFS<sup>+</sup>, unclassified epilepsy, and an alternative syndromal diagnosis <xref ref-type="bibr" rid="bb0010">[2]</xref>. Borderline- and classical GEFS<sup>+</sup> share many characteristics; early-onset febrile seizures with focal epilepsies including FSICs are a phenotype they have in common <xref ref-type="bibr" rid="bb0005">[1]</xref>.</p>
<p>The SCN1A mutation was found in about 10% of GEFS<sup>+</sup> patients. Barba et al. <xref ref-type="bibr" rid="bb0025">[5]</xref> suggested that SCN1A gene mutations and malformations during cortical development may reciprocally affect each other in determining the mechanisms that underlie seizure generation. While sodium channel blockers tend to induce or increase seizures in SCN1A-related seizure disorders <xref ref-type="bibr" rid="bb0030">[6]</xref>, in our patient they were effective and the coordination of anti-seizure drugs resulted in a decrease in her seizures during the follow-up period.</p>
<p>Skjei et al. <xref ref-type="bibr" rid="bb0015">[3]</xref> performed neocortical resection in 6 SCN1A mutation-positive children with drug-resistant epilepsy. Surgical histopathology showed subtle cortical dysplasia in 4 of their patients. They concluded that cortical resection was unlikely to be beneficial due to the genetic defect and unexpected mild diffuse cortical malformations. There is an association between prolonged febrile seizures and TLE with hippocampal sclerosis <xref ref-type="bibr" rid="bb0035">[7]</xref>. A meta-analysis revealed a genome-wide significant association at the sodium-channel gene cluster on chromosome 2q24.3 of SCN1A between mesial TLE with hippocampal sclerosis and febrile seizures <xref ref-type="bibr" rid="bb0040">[8]</xref>. While no patients who had undergone resective surgery for TLE with an SCN1A mutation have been reported, 2 patients with GEFS<sup>+</sup> with an SCN1B mutation were successfully treated by temporal lobectomy <xref ref-type="bibr" rid="bb0045">[9]</xref>. Both had the C121W mutation, a characteristic of the SCN1B mutation; one patient also presented with hippocampal sclerosis.</p>
<p>VNS is effective in patients with many seizure types. It is thought to modulate electrical stimuli to the nucleus tractus solitarius and the brainstem reticular formation, and to interrupt the characteristic synchronous activity of seizures. Morris et al. <xref ref-type="bibr" rid="bb0050">[10]</xref> reported a post-VNS implantation seizure reduction of approximately 50% in 36.8% of patients at year 1, in 43.2% at year 2, and in 42.7% at year 3 after VNS. VNS is also an effective and well-tolerated treatment for patients with Lennox-Gastaut syndrome (LGS), Dravet syndrome, and epilepsy with myoclonic-astatic seizures, and other kind of epileptic encephalopathy (<xref ref-type="table" rid="t0005">Table 1</xref>) <xref ref-type="bibr" rid="bb0055">[11]</xref>, <xref ref-type="bibr" rid="bb0060">[12]</xref>, <xref ref-type="bibr" rid="bb0065">[13]</xref>, <xref ref-type="bibr" rid="bb0070">[14]</xref>, <xref ref-type="bibr" rid="bb0075">[15]</xref>, <xref ref-type="bibr" rid="bb0080">[16]</xref>, <xref ref-type="bibr" rid="bb0085">[17]</xref>, <xref ref-type="bibr" rid="bb0090">[18]</xref>. The initial parameters were set at an output current of 0.25 mA, a signal frequency of 30 Hz, a pulse width of 250–500 ms, stimulation “on”-time 30 s, and stimulation “off”-time 300 s, with the output current generally increased to 2–3 mA as tolerated <xref ref-type="bibr" rid="bb0020">[4]</xref>. A comparison of standard- and rapid stimulation (7 s “on,” 30 s “off”) showed no definitive difference in efficacy. According to the guidelines of the American Academy of Neurology, rapid cycling increases the duty cycle and hastens the need for battery replacement; therefore, the efficacy of rapid cycling must be assessed carefully <xref ref-type="bibr" rid="bb0020">[4]</xref>. McHugh et al. <xref ref-type="bibr" rid="bb0095">[19]</xref> proposed a classification of the outcome after VNS insertion that takes into account both seizure frequency and severity. The status of our patient was comparable to their class 1A 4.5 years after VNS as her seizure reduction exceeded 80% and the ictal or postictal severity was reduced.<table-wrap id="t0005" position="float"><label>Table 1</label><caption><p>Effect of VNS on epilepetic encephalopathy.</p></caption><alt-text id="al0020">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Epilepetic encephalopathy</th><th>Patients with &gt; 50% reduction in seizures</th><th>Follow-up periods (M)</th><th>Study (ref)</th></tr></thead><tbody><tr><td rowspan="3">Dravet syndrome (severe myoclonic epilepsy in infancy)</td><td>50% (4/8)</td><td>12</td><td>Zamponi et al. <xref ref-type="bibr" rid="bb0090">[18]</xref></td></tr><tr><td>38% (5/13) in predominantly GTCS</td><td>24</td><td>Orosz et al. <xref ref-type="bibr" rid="bb0080">[16]</xref></td></tr><tr><td>37% (3/8)</td><td>12</td><td>Dressler et al. <xref ref-type="bibr" rid="bb0070">[14]</xref></td></tr><tr><td>Doose syndrome (epilepsy with myoclonic-astatic seizures)</td><td>67% (2/3)</td><td>Mean 34 (28-40)</td><td>Cersosimo et al. <xref ref-type="bibr" rid="bb0065">[13]</xref></td></tr><tr><td rowspan="3">Lennox–Gastaut syndrome</td><td>65% (30/46)</td><td>Mean 30 (12-108)</td><td>Cersosimo et al. <xref ref-type="bibr" rid="bb0065">[13]</xref></td></tr><tr><td>67% (20/30)</td><td>Mean 52 (17-123)</td><td>Kostov et al. <xref ref-type="bibr" rid="bb0075">[15]</xref></td></tr><tr><td>21% (4/19)</td><td>24</td><td>Aldenkamp et al. <xref ref-type="bibr" rid="bb0055">[11]</xref></td></tr><tr><td>West syndrome</td><td>100% (2/2)</td><td>20 and 24</td><td>Cersosimo et al. <xref ref-type="bibr" rid="bb0065">[13]</xref></td></tr><tr><td>Landau-Kleffner syndrome</td><td>50% (3/6)</td><td>6</td><td>Park <xref ref-type="bibr" rid="bb0085">[17]</xref></td></tr><tr><td>Epilepsy with continuous spikes-and-waves during slow-wave sleep (other than Landau-Kleffner syndrome)</td><td>Seizure-free (a case report)</td><td>12</td><td>Carosella et al. <xref ref-type="bibr" rid="bb0060">[12]</xref></td></tr></tbody></table></table-wrap></p>
<p>Cerebrospinal fluid studies showed a significant increase in GABA 3–4 months after the start of VNS, but no significant decrease in glutamate, aspartate, or 5-HIAA after 3–9 months of VNS <xref ref-type="bibr" rid="bb0050">[10]</xref>. In a mouse model, the SCN1A mutation predominantly impaired sodium-channel activity in GABAergic interneurons and led to decreased inhibition without affecting excitatory cortical pyramidal neurons <xref ref-type="bibr" rid="bb0100">[20]</xref>. This pathogenesis suggests that VNS is a suitable treatment for drug-resistant GEFS<sup>+</sup> with the SCN1A mutation as it exerted favorable effects on Dravet syndrome with the SCN1A mutation <xref ref-type="bibr" rid="bb0090">[18]</xref>.</p>
</sec>
<sec id="s0020">
<label>4</label>
<title>Conclusion</title>
<p>Focal epilepsies with/without impaired consciousness are considerably less common in the GEFS<sup>+</sup> spectrum. VNS reduced both GTCSs and FSICs in our GEFS<sup>+</sup> patient. The seizure reduction was over 75% and 80% in GTCSs and FSICs, respectively, 4 years after the start of VNS. VNS may be a good treatment option in patients with drug-resistant GEFS<sup>+</sup> with both refractory generalized tonic-clonic- and focal seizures.</p>
</sec>
</body>
<back>
<ref-list id="bi0005">
<title>References</title>
<ref id="bb0005">
<label>1</label>
<element-citation id="rf0005" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheffer</surname>
<given-names>I.E.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>F.E.</given-names>
</name>
<name>
<surname>Dibbens</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus?</article-title>
<source/>Brain Dev
          <volume>31</volume>
<year>2009</year>
<fpage>394</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="pmid">19203856</pub-id>
</element-citation>
</ref>
<ref id="bb0010">
<label>2</label>
<element-citation id="rf0010" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Hammond</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Bagguley</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>P.E.</given-names>
</name>
</person-group>
<article-title>Genetic epilepsy with febrile seizures plus: definite and borderline phenotypes</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <volume>83</volume>
<year>2012</year>
<fpage>336</fpage>
<lpage>338</lpage>
<pub-id pub-id-type="pmid">22147072</pub-id>
</element-citation>
</ref>
<ref id="bb0015">
<label>3</label>
<element-citation id="rf0015" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skjei</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Church</surname>
<given-names>E.W.</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>B.N.</given-names>
</name>
<name>
<surname>Santi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Holland-Bouley</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Clancy</surname>
<given-names>R.R.</given-names>
</name>
</person-group>
<article-title>Clinical and histopathological outcomes in patients with SCN1A mutations undergoing surgery for epilepsy</article-title>
<source/>J Neurosurg Pediatr
          <volume>16</volume>
<year>2015</year>
<fpage>668</fpage>
<lpage>674</lpage>
<pub-id pub-id-type="pmid">26339958</pub-id>
</element-citation>
</ref>
<ref id="bb0020">
<label>4</label>
<element-citation id="rf0020" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morris</surname>
<given-names>G.L.</given-names>
<suffix>III</suffix>
</name>
<name>
<surname>Gloss</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Buchhalter</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mack</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Nickels</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Harden</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology</article-title>
<source/>Neurology
          <volume>81</volume>
<year>2013</year>
<fpage>1453</fpage>
<lpage>1459</lpage>
<pub-id pub-id-type="pmid">23986299</pub-id>
</element-citation>
</ref>
<ref id="bb0025">
<label>5</label>
<element-citation id="rf0025" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barba</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Parrini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Coras</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Galuppi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Craiu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kluger</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Co-occurring malformations of cortical development and SCN1A gene mutations</article-title>
<source/>Epilepsia
          <volume>55</volume>
<year>2014</year>
<fpage>1009</fpage>
<lpage>1019</lpage>
<pub-id pub-id-type="pmid">24902755</pub-id>
</element-citation>
</ref>
<ref id="bb0030">
<label>6</label>
<element-citation id="rf0030" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ceulemans</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Boel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Claes</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dom</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Willekens</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Thiry</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Severe myoclonic epilepsy in infancy: toward an optimal treatment</article-title>
<source/>Child Neurol
          <volume>19</volume>
<year>2004</year>
<fpage>516</fpage>
<lpage>521</lpage>
</element-citation>
</ref>
<ref id="bb0035">
<label>7</label>
<element-citation id="rf0035" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varoglu</surname>
<given-names>A.O.</given-names>
</name>
<name>
<surname>Saygi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Acemoglu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ciger</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Prognosis of patients with mesial temporal lobe epilepsy due to hippocampal sclerosis</article-title>
<source/>Epilepsy Res
          <volume>85</volume>
<year>2009</year>
<fpage>206</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="pmid">19345070</pub-id>
</element-citation>
</ref>
<ref id="bb0040">
<label>8</label>
<element-citation id="rf0040" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kasperaviciute</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Catarino</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Matarin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Leu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Novy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tostevin</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A</article-title>
<source/>Brain
          <volume>136</volume>
<year>2013</year>
<fpage>3140</fpage>
<lpage>3150</lpage>
<pub-id pub-id-type="pmid">24014518</pub-id>
</element-citation>
</ref>
<ref id="bb0045">
<label>9</label>
<element-citation id="rf0045" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheffer</surname>
<given-names>I.E.</given-names>
</name>
<name>
<surname>Harkin</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Grinton</surname>
<given-names>B.E.</given-names>
</name>
<name>
<surname>Dibbens</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Zielinski</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Temporal lobe epilepsy and GEFS<sup>+</sup> phenotypes associated with SCN1B mutations</article-title>
<source/>Brain
          <volume>130</volume>
<year>2007</year>
<fpage>100</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="pmid">17020904</pub-id>
</element-citation>
</ref>
<ref id="bb0050">
<label>10</label>
<element-citation id="rf0050" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morris</surname>
<given-names>G.L.</given-names>
<suffix>III</suffix>
</name>
<name>
<surname>Mueller</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>for Vagus Nerve Stimulation Study Group E01-E05</surname>
</name>
</person-group>
<article-title>Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy</article-title>
<source/>Neurology
          <volume>53</volume>
<year>1999</year>
<fpage>1731</fpage>
<lpage>1735</lpage>
<pub-id pub-id-type="pmid">10563620</pub-id>
</element-citation>
</ref>
<ref id="bb0055">
<label>11</label>
<element-citation id="rf0055" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aldenkamp</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Majoie</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Berfelo</surname>
<given-names>M.W.</given-names>
</name>
</person-group>
<article-title>Long-term effects of 24-month treatment with vagus nerve stimulation on behaviour in children with Lennox-Gastaut syndrome</article-title>
<source/>Epilepsy Behav
          <volume>3</volume>
<year>2002</year>
<fpage>475</fpage>
<lpage>479</lpage>
<pub-id pub-id-type="pmid">12609271</pub-id>
</element-citation>
</ref>
<ref id="bb0060">
<label>12</label>
<element-citation id="rf0060" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carosella</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Greiner</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Byars</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>Arthur</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Leach</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Vagus nerve stimulation for electrographic status epilepticus in slow-wave sleep</article-title>
<source/>Pediatr Neurol
          <volume>60</volume>
<year>2016</year>
<fpage>66</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="pmid">27068060</pub-id>
</element-citation>
</ref>
<ref id="bb0065">
<label>13</label>
<element-citation id="rf0065" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cersosimo</surname>
<given-names>R.O.</given-names>
</name>
<name>
<surname>Bartuluchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fortini</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Vagus nerve stimulation: effectiveness and tolerability in 64 paediatric patients with refractory epilepsies</article-title>
<source/>Epileptic Disord
          <volume>13</volume>
<year>2011</year>
<fpage>382</fpage>
<lpage>388</lpage>
<pub-id pub-id-type="pmid">22258042</pub-id>
</element-citation>
</ref>
<ref id="bb0070">
<label>14</label>
<element-citation id="rf0070" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dressler</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Trimmel-Schwahofer</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Reithofer</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Muhlebner</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Groppel</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Reiter-Fink</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Efficacy and tolerability of the ketogenic diet in Dravet Syndrome - Comparison with various standard antiepileptic drug regimens</article-title>
<source/>Epilepsy Res
          <volume>109</volume>
<year>2015</year>
<fpage>81</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="pmid">25524846</pub-id>
</element-citation>
</ref>
<ref id="bb0075">
<label>15</label>
<element-citation id="rf0075" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kostov</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kostov</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Taubøll</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Long-term vagus nerve stimulation in the treatment of Lennox-Gastaut syndrome</article-title>
<source/>Epilepsy Behav
          <volume>16</volume>
<year>2009</year>
<fpage>321</fpage>
<lpage>324</lpage>
<pub-id pub-id-type="pmid">19699154</pub-id>
</element-citation>
</ref>
<ref id="bb0080">
<label>16</label>
<element-citation id="rf0080" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orosz</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>McCormick</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zamponi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Varadkar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Feucht</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Parain</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Vagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24 months in 347 children</article-title>
<source/>Epilepsia
          <volume>55</volume>
<year>2014</year>
<fpage>1576</fpage>
<lpage>1584</lpage>
<pub-id pub-id-type="pmid">25231724</pub-id>
</element-citation>
</ref>
<ref id="bb0085">
<label>17</label>
<element-citation id="rf0085" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>Y.D.</given-names>
</name>
</person-group>
<article-title>The effects of vagus nerve stimulation therapy on patients with intractable seizures and either Landau-Kleffner syndrome or autism</article-title>
<source/>Epilepsy Behav
          <volume>4</volume>
<year>2003</year>
<fpage>286</fpage>
<lpage>290</lpage>
<pub-id pub-id-type="pmid">12791330</pub-id>
</element-citation>
</ref>
<ref id="bb0090">
<label>18</label>
<element-citation id="rf0090" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zamponi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Passamonti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cappanera</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Petrelli</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Clinical course of young patients with Dravet syndrome after vagal nerve stimulation</article-title>
<source/>Eur J Paediatr Neurol
          <volume>15</volume>
<year>2011</year>
<fpage>8</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">20971664</pub-id>
</element-citation>
</ref>
<ref id="bb0095">
<label>19</label>
<element-citation id="rf0095" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McHugh</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Philips</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Doherty</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Delenty</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Outcome measurement after vagal nerve stimulation therapy: proposal of a new classification</article-title>
<source/>Epilepsia
          <volume>48</volume>
<year>2007</year>
<fpage>375</fpage>
<lpage>378</lpage>
<pub-id pub-id-type="pmid">17295633</pub-id>
</element-citation>
</ref>
<ref id="bb0100">
<label>20</label>
<element-citation id="rf0100" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Dutt</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Papale</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Dubé</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Dutton</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>de Haan</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Altered function of the SCN1A voltage-gated sodium channel leads to gamma-aminobutyric acid-ergic (GABAergic) interneuron abnormalities</article-title>
<source/>J Biol Chem
          <volume>285</volume>
<year>2010</year>
<fpage>9823</fpage>
<lpage>9834</lpage>
<pub-id pub-id-type="pmid">20100831</pub-id>
</element-citation>
</ref>
</ref-list>
<ack id="ac0005">
<title>Acknowledgements</title>
<p>Gene analysis was approved by the Ethical Committee of the Fukuoka University School of Medicine, Japan. Gene analysis was supported in part by a Grant-in-Aid for Young Scientists (B) (23791201) (A.I.), a Grant-in-Aid for Scientific Research (A) (24249060 and 151402548) (S.H.), a Grant-in-Aid for Challenging Exploratory Research (25670481) (S.H.), Bilateral Joint Research Projects (S.H.) from the Japan Society for the Promotion of Science (JSPS), Grants for Scientific Research on Innovative Areas (221S0002 and 25129708) (A.I and S.H.) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), a MEXT-supported program from the Strategic Research Foundation at Private Universities 2013-2017 (S.H.), a grant for Practical Research Projects for Rare/Intractable Diseases (15ek0109038a) from the Japan Agency for Medical Research and development (AMED), a grant-in-aid for Research on Measures for Intractable Diseases (H26-Nanji-Ippan-051 and 049) (S.H.) from the Ministry of Health, Labor and Welfare, an Intramural Research Grant (24-7 and 27-5) for Neurological and Psychiatric Disorders of NCNP (S.H.), the Joint Usage/Research Program of the Medical Research Institute, Tokyo Medical and Dental University (S.H.), grants from The Mitsubishi Foundation (S.H.) and the Takeda Scientific Foundation (S.H.), the Kobayashi Magobei Foundation (A.I.), the Kurozumi medical foundation (A.I.), and a Japan Epilepsy Research Foundation grant (A.I.).</p>
</ack>
</back>
</article>
</pmc-articleset>